Evidence map›Paper›PMID 36550781›Full record

ArticleMolecular oncology2023

Single-cell protein profiling defines cell populations associated with triple-negative breast cancer aggressiveness.

Barbora Kvokačková, Radek Fedr, Daniela Kužílková, Jan Stuchlý, Adéla Vávrová, Jiří Navrátil, Pavel Fabian, Róbert Ondruššek, Petra Ovesná, Ján Remšík and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Barbora KvokačkováDepartment of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic.ORCID https://orcid.org/0000-0002-6478-9923
Radek FedrDepartment of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic.
Daniela KužílkováChildhood Leukaemia Investigation Prague, Czech Republic.ORCID https://orcid.org/0000-0001-8086-9790
Jan StuchlýChildhood Leukaemia Investigation Prague, Czech Republic.
Adéla VávrováChildhood Leukaemia Investigation Prague, Czech Republic.
Jiří NavrátilDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Pavel FabianDepartment of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Róbert OndruššekDepartment of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic.
Petra OvesnáInstitute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.ORCID https://orcid.org/0000-0002-3547-5896
Ján RemšíkHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.ORCID https://orcid.org/0000-0002-3228-2896
Jan BouchalDepartment of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic.ORCID https://orcid.org/0000-0003-4842-1720
Tomáš KalinaChildhood Leukaemia Investigation Prague, Czech Republic.ORCID https://orcid.org/0000-0003-4475-2872
Karel SoučekDepartment of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic.ORCID https://orcid.org/0000-0001-7283-8150
Charles University · CZCzech Academy of Sciences · CZMasaryk Memorial Cancer Institute · CZUniversity Hospital Olomouc · CZMasaryk University · CZMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is an aggressive and complex subtype of breast cancer that lacks targeted therapy. TNBC manifests characteristic, extensive intratumoral heterogeneity that promotes disease progression and influences drug response. Single-cell techniques in combination with next-generation computation provide an unprecedented opportunity to identify molecular events with therapeutic potential. Here, we describe the generation of a comprehensive mass cytometry panel for multiparametric detection of 23 phenotypic markers and 13 signaling molecules. This single-cell proteomic approach allowed us to explore the landscape of TNBC heterogeneity, with particular emphasis on the tumor microenvironment. We prospectively profiled freshly resected tumors from 26 TNBC patients. These tumors contained phenotypically distinct subpopulations of cancer and stromal cells that were associated with the patient's clinical status at the time of surgery. We further classified the epithelial-mesenchymal plasticity of tumor cells, and molecularly defined phenotypically diverse populations of tumor-associated stroma. Furthermore, in a retrospective tissue-microarray TNBC cohort, we showed that the level of CD97 at the time of surgery has prognostic potential.

Indexed as

Triple Negative Breast NeoplasmsCell Line, TumorHumansProteomicsRetrospective StudiesSignal TransductionStromal CellsTumor Microenvironmentmass cytometryphenotypic plasticitysingle-cell profilestriple-negative breast cancertumor heterogeneityunsupervised machine learning algorithm

Identifiers

PMID36550781
PMCPMC10257414
OpenAlexW4312113007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.